Although the amount of TTR editing and the durability of the therapeutic effect remain to be established, and this clinical trial is focused on the treatment of polyneuropathy, the high degree of transthyretin reduction observed would be predicted to benefit patients suffering from cardiomyopathy caused by transthyretin amyloidosis. Here, TTR is linked to cardiomyopathy.